[Spasticity and botulinum toxin in 2003. An update].
After the spastic foot in cerebral palsy, there are now wider indications for botulinum toxin injections in spasticity. Post stroke upper limb spasticity has been usefully treated by botulinum toxin in several studies, including double blind placebo-controlled studies. Two serotypes and one serotype B are marketed, with various properties. Botulinum toxin has been studied in multiple etiologies of spasticity. In multiple sclerosis, few studies revealed an efficacy in angulations and comfort. In spinal cord injuries, gait and sphincter disorders can be improved. In post stroke spasticity, lower limb angulations are improved, but gait remained difficult to evaluate. In upper limb spasticity, angulation, function and quality of life were improved in double blind, placebo controlled studies. Comparisons of costs and efficacy are made between botulinum toxin and the other antispastic methods.
Service de Neurologie, Hôpital Léopold-Bellan, Paris. Afeve@aol.com
A
A
Fève
D018726:Anti-Dyskinesia Agents / Q000191:economics / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000188:drug therapy / Q000503:physiopathology; D002986:Clinical Trials as Topic; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology
D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins